Early data: AI-developed drug rentosertib alters 326 proteins and may slow aging
Dr_Singularity · x · 2026-09-07
Early data on rentosertib, a drug candidate developed with AI's help for a rare lung condition, suggests it may also reduce biological hallmarks of aging:
- The drug altered 326 circulating proteins, with analyses pointing to changes in senescence, metabolism, and other aging-related pathways.
- Exploratory organ-specific clocks suggested younger biological profiles in arteries, brain, pancreas, stomach, and the immune system.
- Findings remain early and need confirmation in larger, independent studies.
Related event: AI-Designed IPF Drug Rentosertib Shows Biological Age Reversal in Trial(18 posts)→
More from Research
- Eric Topol challenges frontier-model study: where's proof of sustained upskilling? — EricTopol · 2026-10-27
- New paper: LLM data schedules and learning rate schedules should be co-designed — jasondeanlee · 2026-10-27
- What makes research get adopted: important problems, proper evals, and usability — srchvrs · 2026-10-27
- Bitter lesson part 2: few academic inventions matter, and conference publications aren't the key — srchvrs · 2026-10-27
- First-week PhD student lands ARR Area Chair role, exposing peer-review quirks — anmarasovic · 2026-10-27
- EMNLP keynote: industry does read academic NLP papers, it just rarely credits them — srchvrs · 2026-10-27